QUEBEC CITY, Feb. 16 /PRNewswire/ -- Following on its agreement with Chiron Corporation of Emeryville, California, Infectio Diagnostic Inc. (IDI) of Quebec City has entered into partnership with bioMerieux, a world leader in clinical microbiology.
The agreement specifically stipulates that bioMerieux will receive a licence providing access to part of IDI's intellectual property in the area of identification and bacterial-resistance markers.
According to IDI President, Jean-Pierre Gayral, "This agreement has brought our company to where we can achieve our primary objective - to make IDI a world leader in clinical microbiology - and confirms the value of the technology developed by IDI and the researchers of the Centre de recherche en infectiologie (Infectiology Research Centre) of Universite Laval.
With 5,500 employees globally, bioMerieux is the world's eighth largest biological diagnostics corporation.
This agreement with bioMerieux and the one signed recently with Chiron Corporation will result in the creation of more research and development jobs at IDI's Quebec City facilities.
INFECTIO DIAGNOSTIC INC.
CONTACT: Jacques Milette, Vice President, Marketing and BusinessDevelopment, (418) 681-4343, extension 246, Cellphone:(418) 262-3816